How Bausch Health's Turnaround Progressed In Q4 2025
How Bausch Health's Turnaround Progressed In Q4 2025
Here's What Key Metrics Tell Us About Bausch (BHC) Q4 Earnings
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Q4 Earnings Lag Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.15 per share a year ago.
Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Curious about Bausch (BHC) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Bausch (BHC) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
What to Expect From These Drug/Biotech Players This Earnings Season?
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down
Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.
Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)
Bausch (BHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
2 Strong Mid-Cap Growth Stocks Dan Loeb Bought in Q3
Dan Loeb of Third Point is a brilliant investor worth watching closely whenever the 13F filings roll in.
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
